AstraZeneca biopharma head sees new growth ahead

AstraZeneca’s biopharmaceuticals chief said the unit can deliver substantial growth despite losing patent protection on a major drug and a recent trial setback. He pointed to upcoming launches, late-stage studies and regulatory decisions as potential support for the business.